{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:13:55Z","timestamp":1778228035906,"version":"3.51.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Congenital disorders of glycosylation (CDG) are a group of rare metabolic diseases with heterogeneous presentations, leading to substantial diagnostic challenges, which are poorly understood. Therefore, this study aims to elucidate this diagnostic journey by examining families\u2019 and professionals\u2019 experiences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results and discussion<\/jats:title>\n                <jats:p>A questionnaire was designed for CDG families and professionals, garnering 160 and 35 responses, respectively. Analysis revealed the lack of seizures as a distinctive feature between PMM2-CDG (11.2%) with Other CDG (57.7%) at symptom onset. Hypotonia and developmental disability were prevalent symptoms across all studied CDG. Feeding problems were identified as an early onset symptom in PMM2-CDG (Cramer\u2019s V (V)\u2009=\u20090.30, False Discovery Rate (FDR)\u2009=\u20093.8\u2009\u00d7\u200910<jats:sup>\u2212\u20099<\/jats:sup>), and hypotonia in all studied CDG (V\u2009=\u20090.34, FDR\u2009=\u20097.0\u2009\u00d7\u200910<jats:sup>\u2212\u20093<\/jats:sup>). The average time to diagnosis has decreased in recent years (now ~\u20093.9 years), due to advancements namely the increased use of whole genome and exome sequencing. However, misdiagnoses remain prevalent (PMM2-CDG \u2013 44.9%, non-PMM2-CDG \u2013 64.8%). To address these challenges, we propose adapting medical training to increase awareness of CDG and other rare diseases, ongoing education for physicians, the development of educational resources for relevant medical units, and empowerment of families through patient organizations and support networks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study emphasizes the crucial role of community-centered research, and the insights families can offer to enhance CDG management. By pinpointing existing gaps and needs, our findings can inform targeted interventions and support systems to improve the lives of those impacted by CDG.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03389-2","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T03:05:20Z","timestamp":1730430320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mapping the diagnostic odyssey of congenital disorders of glycosylation (CDG): insights from the community"],"prefix":"10.1186","volume":"19","author":[{"given":"Pedro","family":"Granjo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaak","family":"Jaeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristen","family":"Moors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin A.","family":"Kantautas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula A.","family":"Videira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-2169","authenticated-orcid":false,"given":"Vanessa","family":"dos Reis Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"3389_CR1","doi-asserted-by":"publisher","unstructured":"Donaldson L, Ricciardi W, Sheridan S, Tartaglia R, editors. Textbook of patient safety and clinical risk management. Cham: Springer International Publishing; 2021. https:\/\/doi.org\/10.1007\/978-3-030-59403-9. (accessed April 7, 2023).","DOI":"10.1007\/978-3-030-59403-9"},{"key":"3389_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-022-02270-4","volume":"17","author":"M Benson","year":"2022","unstructured":"Benson M, Albanese A, Bhatia KP, Cavillon P, Cuffe L, K\u00f6nig K, et al. Development of a patient journey map for people living with cervical dystonia. Orphanet J Rare Dis. 2022;17:130. https:\/\/doi.org\/10.1186\/s13023-022-02270-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR3","doi-asserted-by":"publisher","unstructured":"Linda NG, Oliver Sum P, Yong-Jian G. Phases of the diagnostic journey: a Framework. Int Arch Intern Med. 2019;3. https:\/\/doi.org\/10.23937\/2643-4466\/1710013.","DOI":"10.23937\/2643-4466\/1710013"},{"key":"3389_CR4","unstructured":"EU research on rare diseases. n.d. https:\/\/research-and-innovation.ec.europa.eu\/research-area\/health\/rare-diseases_en (accessed August 7, 2023)."},{"key":"3389_CR5","unstructured":"Global Comission. Ending the diagnostic odyssey for children. With a rare disease. 2018. https:\/\/www.cmtc.nl\/wpcontent\/uploads\/2020\/04\/0301-parrish-2.pdf. (accessed August 7, 2023)."},{"key":"3389_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pcl.2016.08.017","volume":"64","author":"D Basel","year":"2017","unstructured":"Basel D, McCarrier J. Ending a diagnostic odyssey: Family Education, Counseling, and response to eventual diagnosis. Pediatr Clin North Am. 2017;64:265\u201372. https:\/\/doi.org\/10.1016\/j.pcl.2016.08.017.","journal-title":"Pediatr Clin North Am"},{"key":"3389_CR7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and Definitions\u2014A systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906\u201314. https:\/\/doi.org\/10.1016\/j.jval.2015.05.008.","journal-title":"Value Health"},{"key":"3389_CR8","unstructured":"Hanscom R, Small M, Lambrecht A. Diagnostic accuracy: room for improvement. 2018. https:\/\/www.coverys.com\/PDFs\/Coverys_Diagnostic_Accuracy_Report.aspx. (accessed August 7, 2023)."},{"key":"3389_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/adc.2007.134940","volume":"93","author":"Y Zurynski","year":"2008","unstructured":"Zurynski Y, Frith K, Leonard H, Elliott E. Rare childhood diseases: how should we respond? Arch Dis Child. 2008;93:1071\u20134. https:\/\/doi.org\/10.1136\/adc.2007.134940.","journal-title":"Arch Dis Child"},{"key":"3389_CR10","doi-asserted-by":"publisher","unstructured":"Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? Parents of children with rare diseases\u2019 experiences of navigating the Healthcare System. J Genet Couns. 2019;28:80\u201390. https:\/\/doi.org\/10.1007\/s10897-018-0294-9.","DOI":"10.1007\/s10897-018-0294-9"},{"key":"3389_CR11","unstructured":"About CDG. | CDG Hub n.d. https:\/\/www.cdghub.com\/about\/. (accessed August 7, 2023)."},{"key":"3389_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ejmg.2017.10.012","volume":"61","author":"R P\u00e9anne","year":"2018","unstructured":"P\u00e9anne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ, Morava E, et al. Congenital disorders of glycosylation (CDG): Quo Vadis? Eur J Med Genet. 2018;61:643\u201363. https:\/\/doi.org\/10.1016\/j.ejmg.2017.10.012.","journal-title":"Eur J Med Genet"},{"key":"3389_CR13","doi-asserted-by":"publisher","first-page":"129751","DOI":"10.1016\/j.bbagen.2020.129751","volume":"1865","author":"N Ondruskova","year":"2021","unstructured":"Ondruskova N, Cechova A, Hansikova H, Honzik T, Jaeken J. Congenital disorders of glycosylation: still hot in 2020. Biochim Biophys Acta BBA - Gen Subj. 2021;1865:129751. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129751.","journal-title":"Biochim Biophys Acta BBA - Gen Subj"},{"key":"3389_CR14","volume-title":"Essent. Glycobiol","author":"P Gagneux","year":"2022","unstructured":"Gagneux P, Hennet T, Varki A. Biological functions of glycans. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, et al. editors. Essent. Glycobiol. 4th ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022.","edition":"4"},{"key":"3389_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10545-011-9299-3","volume":"34","author":"J Jaeken","year":"2011","unstructured":"Jaeken J. Congenital disorders of glycosylation (CDG): it\u2019s (nearly) all in it! J Inherit Metab Dis. 2011;34:853\u20138. https:\/\/doi.org\/10.1007\/s10545-011-9299-3.","journal-title":"J Inherit Metab Dis"},{"key":"3389_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10545-018-0156-5","volume":"41","author":"CR Ferreira","year":"2018","unstructured":"Ferreira CR, Altassan R, Marques-Da-Silva D, Francisco R, Jaeken J, Morava E. Recognizable phenotypes in CDG. J Inherit Metab Dis. 2018;41:541\u201353. https:\/\/doi.org\/10.1007\/s10545-018-0156-5.","journal-title":"J Inherit Metab Dis"},{"key":"3389_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.21037\/atm.2018.10.45","volume":"6","author":"IJ Chang","year":"2018","unstructured":"Chang IJ, He M, Lam CT. Congenital disorders of glycosylation. Ann Transl Med. 2018;6:477\u2013477. https:\/\/doi.org\/10.21037\/atm.2018.10.45.","journal-title":"Ann Transl Med"},{"key":"3389_CR18","doi-asserted-by":"publisher","first-page":"129686","DOI":"10.1016\/j.bbagen.2020.129686","volume":"1864","author":"A G\u00e1mez","year":"2020","unstructured":"G\u00e1mez A, Serrano M, Gallego D, Vilas A, P\u00e9rez B. New and potential strategies for the treatment of PMM2-CDG. Biochim Biophys Acta BBA - Gen Subj. 2020;1864:129686. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129686.","journal-title":"Biochim Biophys Acta BBA - Gen Subj"},{"key":"3389_CR19","doi-asserted-by":"publisher","unstructured":"Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K et al. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Dis Model Mech 2019:dmm040584. https:\/\/doi.org\/10.1242\/dmm.040584","DOI":"10.1242\/dmm.040584"},{"key":"3389_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ana.25457","volume":"85","author":"AF Mart\u00ednez-Monseny","year":"2019","unstructured":"Mart\u00ednez-Monseny AF, Bolasell M, Callej\u00f3n\u2010P\u00f3o L, Cuadras D, Freniche V, Itzep DC, et al. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2\u2010CDG). Ann Neurol. 2019;85:740\u201351. https:\/\/doi.org\/10.1002\/ana.25457.","journal-title":"Ann Neurol"},{"key":"3389_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41436-020-0767-8","volume":"22","author":"P Witters","year":"2020","unstructured":"Witters P, Tahata S, Barone R, \u00d5unap K, Salvarinova R, Gr\u00f8nborg S, et al. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG. Genet Med. 2020;22:1102\u20137. https:\/\/doi.org\/10.1038\/s41436-020-0767-8.","journal-title":"Genet Med"},{"key":"3389_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/adc.85.4.339","volume":"85","author":"CJ Hendriksz","year":"2001","unstructured":"Hendriksz CJ. Successful treatment of carbohydrate deficient glycoprotein syndrome type 1b with oral mannose. Arch Dis Child. 2001;85:339\u201340. https:\/\/doi.org\/10.1136\/adc.85.4.339.","journal-title":"Arch Dis Child"},{"key":"3389_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41436-019-0647-2","volume":"22","author":"J Verheijen","year":"2020","unstructured":"Verheijen J, Tahata S, Kozicz T, Witters P, Morava E. Therapeutic approaches in congenital disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020;22:268\u201379. https:\/\/doi.org\/10.1038\/s41436-019-0647-2.","journal-title":"Genet Med"},{"key":"3389_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-011-9370-0","volume":"34","author":"DJ Lefeber","year":"2011","unstructured":"Lefeber DJ, Morava E, Jaeken J. How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis. 2011;34:849\u201352. https:\/\/doi.org\/10.1007\/s10545-011-9370-0.","journal-title":"J Inherit Metab Dis"},{"key":"3389_CR25","doi-asserted-by":"publisher","unstructured":"Bruneel A, Cholet S, Tran NT, Mai TD, Fenaille F. CDG biochemical screening: where do we stand? Biochim Biophys Acta BBA -. Gen Subj. 2020;1864:129652. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129652.","DOI":"10.1016\/j.bbagen.2020.129652"},{"key":"3389_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13023-023-02879-z","volume":"18","author":"R Francisco","year":"2023","unstructured":"Francisco R, Brasil S, Poejo J, Jaeken J, Pascoal C, Videira PA, et al. Congenital disorders of glycosylation (CDG): state of the art in 2022. Orphanet J Rare Dis. 2023;18:329. https:\/\/doi.org\/10.1186\/s13023-023-02879-z.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2018.11.003","volume":"126","author":"R Francisco","year":"2019","unstructured":"Francisco R, Marques-da-Silva D, Brasil S, Pascoal C, dos Reis Ferreira V, Morava E, et al. The challenge of CDG diagnosis. Mol Genet Metab. 2019;126:1\u20135. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.003.","journal-title":"Mol Genet Metab"},{"key":"3389_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-022-02561-w","volume":"17","author":"K Sandilands","year":"2022","unstructured":"Sandilands K, Williams A, Rylands AJ. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet J Rare Dis. 2022;17:428. https:\/\/doi.org\/10.1186\/s13023-022-02561-w.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR29","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/jcm9072092","volume":"9","author":"R Francisco","year":"2020","unstructured":"Francisco R, Pascoal C, Marques-da-Silva D, Brasil S, Pimentel-Santos FM, Altassan R, et al. New insights into Immunological involvement in congenital disorders of Glycosylation (CDG) from a people-Centric Approach. J Clin Med. 2020;9:2092. https:\/\/doi.org\/10.3390\/jcm9072092.","journal-title":"J Clin Med"},{"key":"3389_CR30","doi-asserted-by":"publisher","first-page":"13506","DOI":"10.3390\/ijerph192013506","volume":"19","author":"R Francisco","year":"2022","unstructured":"Francisco R, Alves S, Gomes C, Granjo P, Pascoal C, Brasil S, et al. A participatory Framework for Plain Language Clinical Management Guideline Development. Int J Environ Res Public Health. 2022;19:13506. https:\/\/doi.org\/10.3390\/ijerph192013506.","journal-title":"Int J Environ Res Public Health"},{"key":"3389_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13023-022-02286-w","volume":"17","author":"R Francisco","year":"2022","unstructured":"Francisco R, Brasil S, Pascoal C, Jaeken J, Liddle M, Videira PA, et al. The road to successful people-centric research in rare diseases: the web-based case study of the Immunology and congenital disorders of Glycosylation questionnaire (ImmunoCDGQ). Orphanet J Rare Dis. 2022;17:134. https:\/\/doi.org\/10.1186\/s13023-022-02286-w.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13023-022-02460-0","volume":"17","author":"M Monticelli","year":"2022","unstructured":"Monticelli M, Francisco R, Brasil S, Marques-da-Silva D, Rijoff T, Pascoal C, et al. Stakeholders\u2019 views on drug development: the congenital disorders of glycosylation community perspective. Orphanet J Rare Dis. 2022;17:303. https:\/\/doi.org\/10.1186\/s13023-022-02460-0.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR33","doi-asserted-by":"publisher","unstructured":"L\u00ea S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. J Stat Softw. 2008;25(1). https:\/\/doi.org\/10.18637\/jss.v025.i01. http:\/\/www.jstatsoft.org\/v25\/i01\/. (accessed April 9, 2023).","DOI":"10.18637\/jss.v025.i01"},{"key":"3389_CR34","unstructured":"Revelle W, Psych. Procedures for psychological, psychometric, and personality research R package version 1.9.12. 2019. https:\/\/CRAN.R-project.org\/package=psych. (accessed April 3, 2023)."},{"key":"3389_CR35","unstructured":"Mayer M. Confidence intervals. Nachdr. Thousand Oaks. Quantitative applications in the social sciences. Calif.: Sage Publ; 2023. p. 93. https:\/\/github.com\/mayer79\/confintr."},{"key":"3389_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s44162-022-00003-6","volume":"1","author":"A Piedade","year":"2022","unstructured":"Piedade A, Francisco R, Jaeken J, Sarkhail P, Brasil S, Ferreira CR, et al. Epidemiology of congenital disorders of glycosylation (CDG)\u2014overview and perspectives. J Rare Dis. 2022;1:3. https:\/\/doi.org\/10.1007\/s44162-022-00003-6.","journal-title":"J Rare Dis"},{"key":"3389_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ejhg.2014.146","volume":"23","author":"J Jaeken","year":"2015","unstructured":"Jaeken J, Lefeber D, Matthijs G. Clinical utility gene card for: ALG6 defective congenital disorder of glycosylation. Eur J Hum Genet. 2015;23:1\u20133. https:\/\/doi.org\/10.1038\/ejhg.2014.146.","journal-title":"Eur J Hum Genet"},{"key":"3389_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-020-01657-5","volume":"16","author":"A Bogda\u0144ska","year":"2021","unstructured":"Bogda\u0144ska A, Lipi\u0144ski P, Szyma\u0144ska-Ro\u017cek P, Jezela-Stanek A, Rokicki D, Socha P, et al. Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up. Orphanet J Rare Dis. 2021;16:17. https:\/\/doi.org\/10.1186\/s13023-020-01657-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-017-0733-y","volume":"13","author":"G-A Kuiper","year":"2018","unstructured":"Kuiper G-A, Meijer OLM, Langereis EJ, Wijburg FA. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis. 2018;13:2. https:\/\/doi.org\/10.1186\/s13023-017-0733-y.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13023-020-01506-5","volume":"15","author":"M Magerl","year":"2020","unstructured":"Magerl M, Gothe H, Krupka S, Lachmann A, Ohlmeier C. A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet J Rare Dis. 2020;15:221. https:\/\/doi.org\/10.1186\/s13023-020-01506-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13023-021-01794-5","volume":"16","author":"AG Sreih","year":"2021","unstructured":"for the Vasculitis Patient-Powered Research Network, Sreih AG, Cronin K, Shaw DG, Young K, Burroughs C, et al. Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet J Rare Dis. 2021;16:184. https:\/\/doi.org\/10.1186\/s13023-021-01794-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR42","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1111\/hex.13625","volume":"25","author":"CQ Nguyen","year":"2022","unstructured":"Nguyen CQ, Kariyawasam D, Alba-Concepcion K, Grattan S, Hetherington K, Wakefield CE, et al. Advocacy groups are the connectors\u2019: experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics. Health Expect. 2022;25:3175\u201391. https:\/\/doi.org\/10.1111\/hex.13625.","journal-title":"Health Expect"},{"key":"3389_CR43","doi-asserted-by":"publisher","unstructured":"Starosta RT, Tarnowski J, Vairo FP e, Raymond K, Preston G, Morava E. Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) initially diagnosed as ALG6-CDG: Functional evidence for benignity of the ALG6 c.391T\u2009>\u2009C (p.Tyr131His) variant and further expanding the BBSOAS phenotype. Eur J Med Genet. 2020;63:103941. https:\/\/doi.org\/10.1016\/j.ejmg.2020.103941","DOI":"10.1016\/j.ejmg.2020.103941"},{"key":"3389_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13023-020-01660-w","volume":"16","author":"MK Depping","year":"2021","unstructured":"Depping MK, Uhlenbusch N, von Kodolitsch Y, Klose HFE, Mautner V-F, L\u00f6we B. Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study. Orphanet J Rare Dis. 2021;16:44. https:\/\/doi.org\/10.1186\/s13023-020-01660-w.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR45","unstructured":"Centers for Disease Control and Prevention. Talking points about health literacy. 2021. https:\/\/www.cdc.gov\/healthliteracy\/shareinteract\/TellOthers.html. (accessed January 27, 2023)."},{"key":"3389_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/brainsci11010088","volume":"11","author":"J Paprocka","year":"2021","unstructured":"Paprocka J, Jezela-Stanek A, Tylki-Szyma\u0144ska A, Grunewald S. Congenital Disorders of Glycosylation from a neurological perspective. Brain Sci. 2021;11:88. https:\/\/doi.org\/10.3390\/brainsci11010088.","journal-title":"Brain Sci"},{"key":"3389_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/8904_2015_497","volume-title":"JIMD reports","author":"A Fiumara","year":"2015","unstructured":"Fiumara A, Barone R, Del Campo G, Striano P, Jaeken J. Electroclinical features of early-onset epileptic encephalopathies in congenital disorders of glycosylation (CDGs). In: Morava E, Baumgartner M, Patterson M, Rahman S, Zschocke J, Peters V, editors. JIMD reports. Volume 27. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. pp. 93\u20139. https:\/\/doi.org\/10.1007\/8904_2015_497."},{"key":"3389_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jmg.38.1.14","volume":"38","author":"P de Lonlay","year":"2001","unstructured":"de Lonlay P, Seta N, Barrot S, Chabrol B, Drouin V, Gabriel BM, et al. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet. 2001;38:14\u20139. https:\/\/doi.org\/10.1136\/jmg.38.1.14.","journal-title":"J Med Genet"},{"key":"3389_CR49","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/epi.16545","volume":"61","author":"A Bayat","year":"2020","unstructured":"Bayat A, Knaus A, Pendziwiat M, Afenjar A, Barakat TS, Bosch F, et al. Lessons learned from 40 novel PIGA patients and a review of the literature. Epilepsia. 2020;61:1142\u201355. https:\/\/doi.org\/10.1111\/epi.16545.","journal-title":"Epilepsia"},{"key":"3389_CR50","doi-asserted-by":"publisher","first-page":"2329048X2311537","DOI":"10.1177\/2329048X231153781","volume":"10","author":"DJ Clark","year":"2023","unstructured":"Clark DJ, Murray T, Drees M, Kulkarni N. A Case of ALG6-CDG with Explosive Onset of Intractable Epilepsy during Infancy. Child Neurol Open. 2023;10:2329048X2311537. https:\/\/doi.org\/10.1177\/2329048X231153781.","journal-title":"Child Neurol Open"},{"key":"3389_CR51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/jmedgenet-2017-104903","volume":"54","author":"M Schiff","year":"2017","unstructured":"Schiff M, Roda C, Monin M-L, Arion A, Barth M, Bednarek N, et al. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. J Med Genet. 2017;54:843\u201351. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104903.","journal-title":"J Med Genet"},{"key":"3389_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jimd.12024","volume":"42","author":"R Altassan","year":"2019","unstructured":"Altassan R, P\u00e9anne R, Jaeken J, Barone R, Bidet M, Borgel D, et al. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: diagnosis, treatment and follow up. J Inherit Metab Dis. 2019;42:5\u201328. https:\/\/doi.org\/10.1002\/jimd.12024.","journal-title":"J Inherit Metab Dis"},{"key":"3389_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10545-016-0012-4","volume":"40","author":"D Marques-da-Silva","year":"2017","unstructured":"Marques-da-Silva D, dos Reis Ferreira V, Monticelli M, Janeiro P, Videira PA, Witters P, et al. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J Inherit Metab Dis. 2017;40:195\u2013207. https:\/\/doi.org\/10.1007\/s10545-016-0012-4.","journal-title":"J Inherit Metab Dis"},{"key":"3389_CR54","doi-asserted-by":"publisher","first-page":"107606","DOI":"10.1016\/j.ymgme.2023.107606","volume":"139","author":"D De Graef","year":"2023","unstructured":"De Graef D, Ligezka AN, Rezents J, Mazza GL, Preston G, Schwartz K, et al. Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation. Mol Genet Metab. 2023;139:107606. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107606.","journal-title":"Mol Genet Metab"},{"key":"3389_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymgme.2013.02.006","volume":"109","author":"M Linssen","year":"2013","unstructured":"Linssen M, Mohamed M, Wevers RA, Lefeber DJ, Morava E. Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab. 2013;109:107\u201311. https:\/\/doi.org\/10.1016\/j.ymgme.2013.02.006.","journal-title":"Mol Genet Metab"},{"key":"3389_CR56","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.rpth.2023.100142","volume":"7","author":"T Pascreau","year":"2023","unstructured":"Pascreau T, Auditeau C, Borgel D. Hemostatic defects in congenital disorders of glycosylation. Res Pract Thromb Haemost. 2023;7:100142. https:\/\/doi.org\/10.1016\/j.rpth.2023.100142.","journal-title":"Res Pract Thromb Haemost"},{"key":"3389_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jpeds.2016.12.060","volume":"183","author":"C P\u00e9rez-Cerd\u00e1","year":"2017","unstructured":"P\u00e9rez-Cerd\u00e1 C, Gir\u00f3s ML, Serrano M, Ecay MJ, Gort L, P\u00e9rez Due\u00f1as B, et al. A Population-based study on congenital disorders of protein N- and combined with O-Glycosylation experience in clinical and genetic diagnosis. J Pediatr. 2017;183:170\u2013e1771. https:\/\/doi.org\/10.1016\/j.jpeds.2016.12.060.","journal-title":"J Pediatr"},{"key":"3389_CR58","doi-asserted-by":"publisher","first-page":"13200","DOI":"10.1073\/pnas.95.22.13200","volume":"95","author":"C K\u00f6rner","year":"1998","unstructured":"K\u00f6rner C, Knauer R, Holzbach U, Hanefeld F, Lehle L, von Figura K. Carbohydrate-deficient glycoprotein syndrome type V: Deficiency of dolichyl- P -Glc:Man 9 GlcNAc 2 - PP -dolichyl glucosyltransferase. Proc Natl Acad Sci. 1998;95:13200\u20135. https:\/\/doi.org\/10.1073\/pnas.95.22.13200.","journal-title":"Proc Natl Acad Sci"},{"key":"3389_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00415-014-7549-7","volume":"262","author":"R Barone","year":"2015","unstructured":"Barone R, Carrozzi M, Parini R, Battini R, Martinelli D, Elia M, et al. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation. J Neurol. 2015;262:154\u201364. https:\/\/doi.org\/10.1007\/s00415-014-7549-7.","journal-title":"J Neurol"},{"key":"3389_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-020-2434-2","volume":"583","author":"E Turro","year":"2020","unstructured":"Turro E, Astle WJ, Megy K, Gr\u00e4f S, Greene D, Shamardina O, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020;583:96\u2013102. https:\/\/doi.org\/10.1038\/s41586-020-2434-2.","journal-title":"Nature"},{"key":"3389_CR61","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1177\/15353702211040046","volume":"246","author":"H Nisar","year":"2021","unstructured":"Nisar H, Wajid B, Shahid S, Anwar F, Wajid I, Khatoon A, et al. Whole-genome sequencing as a first-tier diagnostic framework for rare genetic diseases. Exp Biol Med. 2021;246:2610\u20137. https:\/\/doi.org\/10.1177\/15353702211040046.","journal-title":"Exp Biol Med"},{"key":"3389_CR62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/gim.2017.162","volume":"20","author":"S Nambot","year":"2018","unstructured":"Nambot S, Thevenon J, Kuentz P, Duffourd Y, Tisserant E, Bruel A-L, et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and\/or intellectual disability: substantial interest of prospective annual reanalysis. Genet Med. 2018;20:645\u201354. https:\/\/doi.org\/10.1038\/gim.2017.162.","journal-title":"Genet Med"},{"key":"3389_CR63","doi-asserted-by":"publisher","first-page":"263300402312192","DOI":"10.1177\/26330040231219272","volume":"4","author":"JM Lumsden","year":"2023","unstructured":"Lumsden JM, Urv TK. The Rare diseases Clinical Research Network: a model for clinical trial readiness. Ther Adv Rare Dis. 2023;4:26330040231219272. https:\/\/doi.org\/10.1177\/26330040231219272.","journal-title":"Ther Adv Rare Dis"},{"key":"3389_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/978-3-319-67144-4_30","volume-title":"Rare dis. Epidemiol. Update overv","author":"AM Moliner","year":"2017","unstructured":"Moliner AM, Waligora J. The European Union Policy in the field of Rare diseases. In: de la Posada M, Taruscio D, Groft SC, editors. Rare dis. Epidemiol. Update overv. Cham: Springer International Publishing; 2017. pp. 561\u201387. https:\/\/doi.org\/10.1007\/978-3-319-67144-4_30."},{"key":"3389_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12687-015-0224-6","volume":"6","author":"DG Melo","year":"2015","unstructured":"Melo DG, De Paula PK, De Araujo Rodrigues S, Da Silva De Av\u00f3 LR, Germano CMR, Demarzo MMP. Genetics in primary health care and the National Policy on Comprehensive Care for people with Rare diseases in Brazil: opportunities and challenges for professional education. J Community Genet. 2015;6:231\u201340. https:\/\/doi.org\/10.1007\/s12687-015-0224-6.","journal-title":"J Community Genet"},{"key":"3389_CR66","doi-asserted-by":"publisher","first-page":"100434","DOI":"10.1016\/j.lana.2023.100434","volume":"18","author":"D Wainstock","year":"2023","unstructured":"Wainstock D, Katz A. Advancing rare disease policy in Latin America: a call to action. Lancet Reg Health - Am. 2023;18:100434. https:\/\/doi.org\/10.1016\/j.lana.2023.100434.","journal-title":"Lancet Reg Health - Am"},{"key":"3389_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ymgme.2020.01.004","volume":"129","author":"D Taruscio","year":"2020","unstructured":"Taruscio D, Baynam G, Cederroth H, Groft SC, Klee EW, Kosaki K, et al. The Undiagnosed Diseases Network International: five years and more! Mol Genet Metab. 2020;129:243\u201354. https:\/\/doi.org\/10.1016\/j.ymgme.2020.01.004.","journal-title":"Mol Genet Metab"},{"key":"3389_CR68","unstructured":"Frontiers in Congenital Disorders of Glycosylation n. d. https:\/\/fcdgc.rarediseasesnetwork.org\/ (accessed May 17, 2023)."},{"key":"3389_CR69","unstructured":"MetabERN. European Refence Network for Hereditary Metabolic Disorders n.d. https:\/\/metab.ern-net.eu\/ (accessed August 7, 2023)."},{"key":"3389_CR70","unstructured":"EUROGLYCAN-omics. congenital errors of glycosylation n.d. https:\/\/researchportal.be\/en\/project\/euroglycan-omics-congenital-errors-glycosylation (accessed May 17, 2023)."},{"key":"3389_CR71","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/genes10120978","volume":"10","author":"S Brasil","year":"2019","unstructured":"Brasil S, Pascoal C, Francisco R, dos Reis Ferreira V, Videira A, Valad\u00e3o P. Artificial Intelligence (AI) in Rare diseases: is the future. Brighter? Genes. 2019;10:978. https:\/\/doi.org\/10.3390\/genes10120978.","journal-title":"Brighter? Genes"},{"key":"3389_CR72","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/cts.13619","volume":"16","author":"M Wojtara","year":"2023","unstructured":"Wojtara M, Rana E, Rahman T, Khanna P, Singh H. Artificial intelligence in rare disease diagnosis and treatment. Clin Transl Sci. 2023;16:2106\u201311. https:\/\/doi.org\/10.1111\/cts.13619.","journal-title":"Clin Transl Sci"},{"key":"3389_CR73","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12913-017-2625-1","volume":"17","author":"C De Freitas","year":"2017","unstructured":"De Freitas C, Dos Reis V, Silva S, Videira PA, Morava E, Jaeken J. Public and patient involvement in needs assessment and social innovation: a people-centred approach to care and research for congenital disorders of glycosylation. BMC Health Serv Res. 2017;17:682. https:\/\/doi.org\/10.1186\/s12913-017-2625-1.","journal-title":"BMC Health Serv Res"},{"key":"3389_CR74","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/jep.12281","volume":"21","author":"E Ramalle-G\u00f3mara","year":"2015","unstructured":"Ramalle-G\u00f3mara E, Ruiz E, Qui\u00f1ones C, Andr\u00e9s S, Iruzubieta J, Gil-de-G\u00f3mez J. General knowledge and opinion of future health care and non-health care professionals on rare diseases: opinion on rare diseases. J Eval Clin Pract. 2015;21:198\u2013201. https:\/\/doi.org\/10.1111\/jep.12281.","journal-title":"J Eval Clin Pract"},{"key":"3389_CR75","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-020-01432-6","volume":"15","author":"D Walkowiak","year":"2020","unstructured":"Walkowiak D, Domaradzki J. Needs assessment study of rare diseases education for nurses and nursing students in Poland. Orphanet J Rare Dis. 2020;15:167. https:\/\/doi.org\/10.1186\/s13023-020-01432-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR76","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.healthpol.2012.02.018","volume":"105","author":"K Budych","year":"2012","unstructured":"Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient\u2013physician interaction. Health Policy. 2012;105:154\u201364. https:\/\/doi.org\/10.1016\/j.healthpol.2012.02.018.","journal-title":"Health Policy"},{"key":"3389_CR77","doi-asserted-by":"publisher","first-page":"639610","DOI":"10.3389\/fgene.2021.639610","volume":"12","author":"J Domaradzki","year":"2021","unstructured":"Domaradzki J, Walkowiak D, Knowledge, Attitudes of Future Healthcare Professionals Toward Rare Diseases. Front Genet. 2021;12:639610. https:\/\/doi.org\/10.3389\/fgene.2021.639610.","journal-title":"Front Genet"},{"key":"3389_CR78","unstructured":"Posada M, Carroquino MJ, P\u00e9rez MH. EUROPEAN PROJECT FOR RARE DISEASES NATIONAL PLANS DEVELOPMENT 2011."},{"key":"3389_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12687-021-00521-8","volume":"12","author":"B Tumiene","year":"2021","unstructured":"Tumiene B, Graessner H, Mathijssen IM, Pereira AM, Schaefer F, Scarpa M, et al. European reference networks: challenges and opportunities. J Community Genet. 2021;12:217\u201329. https:\/\/doi.org\/10.1007\/s12687-021-00521-8.","journal-title":"J Community Genet"},{"key":"3389_CR80","doi-asserted-by":"crossref","unstructured":"Kope\u0107 G, Podolec P. Establishing a curriculum on rare diseases for medical students. J Rare Cardiovasc Dis 2015;2.","DOI":"10.20418\/jrcd.vol2no3.194"},{"key":"3389_CR81","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.amjmed.2023.02.010","volume":"136","author":"S Ranganathan","year":"2023","unstructured":"Ranganathan S, Prasad V. CME: is it meeting the Mark? Am J Med. 2023;136:618\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2023.02.010.","journal-title":"Am J Med"},{"key":"3389_CR82","unstructured":"CDG CARE Patient E-Brochure n. d. https:\/\/cdgcare.org\/wp-content\/uploads\/2023\/02\/CDG-CARE-Patient-E-Brochure.pdf (accessed April 9, 2023)."},{"key":"3389_CR83","unstructured":"Resource Library | World CDG Organization. https:\/\/worldcdg.org\/resources?resources=&type=266. (accessed April 17, 2023)."},{"key":"3389_CR84","unstructured":"CDG Care - Resources. CDG Care n.d. https:\/\/cdgcare.org\/resources\/ (accessed May 17, 2023)."},{"key":"3389_CR85","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/ijerph20020968","volume":"20","author":"M Falc\u00e3o","year":"2023","unstructured":"Falc\u00e3o M, Allocca M, Rodrigues AS, Granjo P, Francisco R, Pascoal C, et al. A community-based participatory Framework to Co-develop Patient Education materials (PEMs) for Rare diseases: a Model Transferable across diseases. Int J Environ Res Public Health. 2023;20:968. https:\/\/doi.org\/10.3390\/ijerph20020968.","journal-title":"Int J Environ Res Public Health"},{"key":"3389_CR86","unstructured":"CDG Connect Patient Insights Network. https:\/\/connect.invitae.com\/en\/org\/cdg  (accessed April 9, 2023)."},{"key":"3389_CR87","unstructured":"Inherited Glycosylphosphatidylinositol Deficiency (IGD). Disorders medical history collection and registry. https:\/\/redcap01.brisc.utah.edu\/ccts\/redcap\/surveys\/?s=R4HKREWNY4D7XF9T (accessed April 9, 2023)."},{"key":"3389_CR88","unstructured":"CDG Care - Research. CDG Care n.d. https:\/\/cdgcare.org\/research\/ (accessed May 17, 2023)."},{"key":"3389_CR89","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13023-022-02551-y","volume":"17","author":"C Pascoal","year":"2022","unstructured":"Pascoal C, Ferreira I, Teixeira C, Almeida E, Slade A, Brasil S, et al. Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals. Orphanet J Rare Dis. 2022;17:398. https:\/\/doi.org\/10.1186\/s13023-022-02551-y.","journal-title":"Orphanet J Rare Dis"},{"key":"3389_CR90","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.3390\/ijerph19116829","volume":"19","author":"R Francisco","year":"2022","unstructured":"Francisco R, Brasil S, Pascoal C, Edmondson AC, Jaeken J, Videira PA, et al. A Community-Led Approach as a guide to Overcome Challenges for Therapy Research in congenital disorders of Glycosylation. Int J Environ Res Public Health. 2022;19:6829. https:\/\/doi.org\/10.3390\/ijerph19116829.","journal-title":"Int J Environ Res Public Health"},{"key":"3389_CR91","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-018-0802-x","volume":"13","author":"O Pogoryelova","year":"2018","unstructured":"Pogoryelova O, Gonz\u00e1lez Coraspe JA, Nikolenko N, Lochm\u00fcller H, Roos A. GNE myopathy: from clinics and genetics to pathology and research strategies. Orphanet J Rare Dis. 2018;13:70. https:\/\/doi.org\/10.1186\/s13023-018-0802-x.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03389-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03389-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T03:08:40Z","timestamp":1730430520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03389-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03389-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Faculty of Psychology, University of Lisbon (19 July 2021). An informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tristen Moors has declared a financial interest due to employment with Glycomine, Inc. This connection might be considered as a competing interest. Similarly, Kristin A. Kantautas has a financial interest through employment with Perlara, which could also be seen as a competing interest. The other authors involved in this work have declared that they have no known competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}